Literature DB >> 18765558

Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer.

Olivier Cussenot1, Abdel-Rahmène Azzouzi, Gladys Bantsimba-Malanda, Cecile Gaffory, Philippe Mangin, Luc Cormier, Georges Fournier, Antoine Valeri, Lionel Jouffe, Morgan Roupret, Gaelle Fromont, Mathilde Sibony, Eva Comperat, Géraldine Cancel-Tassin.   

Abstract

PURPOSE: Recently, two independent loci located at 8q24 that contribute to prostate cancer risk in men of European origin were identified. EXPERIMENTAL
DESIGN: Using Bayesian probability network and logistic regression model, we searched for associations between 34 single-nucleotide polymorphisms (SNP) located at 8q24 and the aggressiveness patterns of prostate adenocarcinoma or familial history of cancers in 823 White Caucasian French men.
RESULTS: Probability network according to the Markov chain algorithm separated the SNPs into two main groups: The first one was linked to the locus marked by rs6983267 and the second one was linked to the locus marked by rs1447295. When the patients were stratified according to tumor stage and prostate-specific antigen value, the association between the variant genotypes from six SNPs located in the second network and prostate cancer risk was strongest or confined to the patients from the more aggressive classes. However, the association between prostate cancer risk and the CC genotype of rs7841264, which marked the recombination hotspot at 8q24, was confined to patients with the highest Gleason score (odds ratio, 2.15; 95% confidence interval, 1.27-3.64; P=0.004). Interestingly, the G allele of rs6983267 was associated with familial prostate cancer risk.
CONCLUSIONS: Our data further support that variability at 8q24 is associated with a high risk of aggressive prostate cancer at diagnosis and is linked with familial history of prostate cancer. These results corroborate that 8q24 SNPs must be evaluated in terms of prostate cancer aggressiveness markers to optimize early diagnosis procedures and management of the disease.

Entities:  

Mesh:

Year:  2008        PMID: 18765558     DOI: 10.1158/1078-0432.CCR-07-4999

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  14 in total

1.  Common variants at 8q24 are associated with prostate cancer risk in Serbian population.

Authors:  Ana S Branković; Goran N Brajušković; Jovan D Mirčetić; Zorana Z Nikolić; Predrag B Kalaba; Vinka D Vukotić; Saša M Tomović; Snežana J Cerović; Zoran A Radojičić; Dušanka L J Savić-Pavićević; Stanka P Romac
Journal:  Pathol Oncol Res       Date:  2013-03-28       Impact factor: 3.201

2.  Number of prostate cancer risk alleles may identify possibly 'insignificant' disease.

Authors:  Brian T Helfand; Stacy Loeb; Donghui Kan; William J Catalona
Journal:  BJU Int       Date:  2010-12       Impact factor: 5.588

3.  Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence.

Authors:  Jiyoung Ahn; Adam S Kibel; Jong Y Park; Timothy R Rebbeck; Hanna Rennert; Janet L Stanford; Elaine A Ostrander; Stephen Chanock; Ming-Hsi Wang; Rama D Mittal; William B Isaacs; Elizabeth A Platz; Richard B Hayes
Journal:  Clin Cancer Res       Date:  2011-02-22       Impact factor: 12.531

4.  Early onset prostate cancer has a significant genetic component.

Authors:  Ethan M Lange; Claudia A Salinas; Kimberly A Zuhlke; Anna M Ray; Yunfei Wang; Yurong Lu; Lindsey A Ho; Jingchun Luo; Kathleen A Cooney
Journal:  Prostate       Date:  2011-05-02       Impact factor: 4.104

5.  Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans.

Authors:  Jeannette T Bensen; Zongli Xu; Gary J Smith; James L Mohler; Elizabeth T H Fontham; Jack A Taylor
Journal:  Prostate       Date:  2012-05-01       Impact factor: 4.104

6.  Impact of genotyping on outcome of prostatic biopsies: a multicenter prospective study.

Authors:  Jean-Nicolas Cornu; Sarah Drouin; Géraldine Cancel-Tassin; Pierre Bigot; Abdel-Rahmène Azzouzi; Nicolas Koutlidis; Luc Cormier; Cécile Gaffory; Morgan Rouprêt; Philippe Sèbe; Marc-Olivier Bitker; François Haab; Olivier Cussenot
Journal:  Mol Med       Date:  2011-02-04       Impact factor: 6.354

7.  Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohort.

Authors:  Chee L Goh; Edward J Saunders; Daniel A Leongamornlert; Malgorzata Tymrakiewicz; Karen Thomas; Elizabeth D Selvadurai; Ruth Woode-Amissah; Tokhir Dadaev; Nadiya Mahmud; Elena Castro; David Olmos; Michelle Guy; Koveela Govindasami; Lynne T O'Brien; Amanda L Hall; Rosemary A Wilkinson; Emma J Sawyer; Ali Amin Al Olama; Douglas F Easton; Zsofia Kote-Jarai; Chris C Parker; Rosalind A Eeles
Journal:  BJU Int       Date:  2013-01-15       Impact factor: 5.588

8.  8q24 sequence variants in relation to prostate cancer risk among men of African descent: a case-control study.

Authors:  Marnita L Benford; Tiva T VanCleave; Nicole A Lavender; Rick A Kittles; LaCreis R Kidd
Journal:  BMC Cancer       Date:  2010-06-28       Impact factor: 4.430

9.  Bladder cancer SNP panel predicts susceptibility and survival.

Authors:  Angeline S Andrew; Jiang Gui; Arthur C Sanderson; Rebecca A Mason; Elaine V Morlock; Alan R Schned; Karl T Kelsey; Carmen J Marsit; Jason H Moore; Margaret R Karagas
Journal:  Hum Genet       Date:  2009-03-01       Impact factor: 4.132

Review 10.  The genetic epidemiology of prostate cancer and its clinical implications.

Authors:  Rosalind Eeles; Chee Goh; Elena Castro; Elizabeth Bancroft; Michelle Guy; Ali Amin Al Olama; Douglas Easton; Zsofia Kote-Jarai
Journal:  Nat Rev Urol       Date:  2013-12-03       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.